Hypertrophic cardiomyopathy can be a debilitating condition that currently has no approved therapies to treat it, highlighting the impact of potential treatments like mavacamten, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
Hypertrophic cardiomyopathy can be a debilitating condition that currently has no approved therapies to treat it, highlighting the impact of potential treatments like mavacamten, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
Transcript
What are the clinical and cost burdens of hypertrophic cardiomyopathy on the U.S. health system? Is the burden from this condition increasing?
Hypertrophic cardiomyopathy is a fairly common form of cardiomyopathy—it affects 1 in 500 people in the United States and globally. Hypertrophic cardiomyopathy manifests in a variety of ways for patients. Some people are able to get by with minimal symptoms through a large part of their life. For others, they’re impacted by heart failure, atrial fibrillation, ventricular fibrillation, sudden cardiac death, worsening heart failure–so, it really actually presents in a variety of ways. For some people, they’re just limited by activities of daily living. For others, it actually can really be quite debilitating, and their only options end up being surgery or even heart transplantation.
With the recent JAMA Cardiology study showing an increase in heart failure in the US population, where does mavacamten fit into the treatment paradigm?
Mavacamten is being developed for obstructive hypertrophic cardiomyopathy—we’re in phase 3 in that study. So, this is a sub-form of heart failure–so it’s patients with heart failure that’s due to actually the heart actually working in overtime. It’d be like basically your bicep muscles having to work 24 hours a day, 7 days a week every day of your life. They just become so very big, thick, and frankly so non-compliant that actually they don’t end up working very well–the heart is not able to fill well with blood and it ends up actually leading to a heart failure for those patients there. So, it’s a very specialized form of heart failure. We think that the molecular mechanisms of hypertrophic cardiomyopathy may actually give us insight how to treat some patients with heart failure with preserved ejection fraction. It makes up approximately half of all of heart failure in the US, and we presently don’t have any therapies that are approved for that.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More